



## PHARMACEUTICAL 2022



**B**IOMARIN®





## PHARMACEUTICAL 2022



**B**OMARIN

## BIOMARIN PHARMACEUTICAL INC Rank 55 of 475

The relative strengths and weaknesses of BIOMARIN PHARMACEUTICAL INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOMARIN PHARMACEUTICAL INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 231% points. The greatest weakness of BIOMARIN PHARMACEUTICAL INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 116%, being 393% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	2,274,385
Cost of Goods Sold	470,515
Intangible Assets	584,851
Liabilities, Current	539,822
Liabilities, Non-Current	98,519
Other Assets	2,108,628
Other Compr. Net Income	30,571
Other Expenses	74,000
Other Liabilities	1,094,244
Other Net Income	22,328
Property and Equipment	1,035,461
Research and Development	628,793
Revenues	1,846,275
Selling, General and Administrative Expense	759,375

Output Variable	Value in 1000 USD
Assets	6,003,325
Liabilities	1,732,585
Expenses	1,932,683
Stockholders Equity	4,270,740
Net Income	-64,080
Comprehensive Net Income	-48,794
Economic Capital Ratio	116%